Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alternative iron-depleted media for cefiderocol susceptibility testing.
Eales BM, Smith JE, Pouya N, Teran NS, Miller WR, Tam VH. Eales BM, et al. Among authors: tam vh. Int J Antimicrob Agents. 2024 May 7:107193. doi: 10.1016/j.ijantimicag.2024.107193. Online ahead of print. Int J Antimicrob Agents. 2024. PMID: 38723696 No abstract available.
An All-Soluble Fe/Mn-Based Alkaline Redox Flow Battery System.
Shen X, Kellamis C, Tam V, Sinclair N, Wainright J, Savinell R. Shen X, et al. Among authors: tam v. ACS Appl Mater Interfaces. 2024 Apr 17;16(15):18686-18692. doi: 10.1021/acsami.3c15803. Epub 2024 Apr 4. ACS Appl Mater Interfaces. 2024. PMID: 38573309
Comparison of cefiderocol in-vitro susceptibility testing modalities.
Teran NS, Vuong L, Phe K, Lasco TM, Miller WR, Tam VH. Teran NS, et al. Among authors: tam vh. J Glob Antimicrob Resist. 2024 Mar 27;37:100-101. doi: 10.1016/j.jgar.2024.03.011. Online ahead of print. J Glob Antimicrob Resist. 2024. PMID: 38552875 Free article. No abstract available.
Lessons Learned from a Citywide Abandoned Housing Experiment.
MacDonald J, Jacobowitz A, Gravel J, Smith M, Stokes R, Tam V, South E, Branas C. MacDonald J, et al. Among authors: tam v. J Am Plann Assoc. 2024;90(1):159-172. doi: 10.1080/01944363.2022.2128855. Epub 2023 Feb 3. J Am Plann Assoc. 2024. PMID: 38405027
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: tam vc. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
In vitro and in vivo models define a molecular signature reference for human embryonic notochordal cells.
Warin J, Vedrenne N, Tam V, Zhu M, Yin D, Lin X, Guidoux-D'halluin B, Humeau A, Roseiro L, Paillat L, Chédeville C, Chariau C, Riemers F, Templin M, Guicheux J, Tryfonidou MA, Ho JWK, David L, Chan D, Camus A. Warin J, et al. Among authors: tam v. iScience. 2024 Jan 26;27(2):109018. doi: 10.1016/j.isci.2024.109018. eCollection 2024 Feb 16. iScience. 2024. PMID: 38357665 Free PMC article.
514 results